Steven Globerman - Kindersley Clarion

Canada’s upstream oil and gas sector is in intensive care

Posted by Steven Globerman | May 8, 2019

The economic damage to the energy industry is due largely to government regulatory and tax policies

Posted by Bacchus Barua | Feb 24, 2019

There’s no escaping the fact that discovering, developing and testing new drugs costs a lot of money

Posted by Steven Globerman | Jan 16, 2019

Burdensome regulation, limited competition and unfavourable taxes hold Canadian companies back

Posted by Steven Globerman | Dec 6, 2018

A shift in U.S. drug pricing could cut pharmaceutical profits, meaning less money for research and development

Posted by Steven Globerman | Oct 23, 2018

There’s been no growth in years in the corporate assets that help make companies more efficient and profitable